Posted: June 15, 2014 at 8:41 am
FINITI: Cellular Aging Ends Here
FINITI contains the only proprietary blend of natural ingredients known to safely lengthen short telomeres and maintain healthy stem cells. It also protects your DNA, telomeres, and cells...
By: HealthBeauty@Jeunesse
See original here:
FINITI: Cellular Aging Ends Here - Video
Posted: June 15, 2014 at 8:41 am
Doctor uses stem cells
To heal patient.
By: WTNH News8
Read this article:
Doctor uses stem cells - Video
Posted: June 15, 2014 at 8:41 am
Stem Cell Therapy for Anti-Aging Treatment, How it works?
http://www.placidway.com/package/1023/Affordable-Therapeutic-Treatment-In-Lugano%2C-Switzerland - Antiaging treatments have been and will continue to be a hot topic among men and women of all...
By: placidways
Originally posted here:
Stem Cell Therapy for Anti-Aging Treatment, How it works? - Video
Posted: June 14, 2014 at 2:44 pm
Poway, CA (PRWEB) June 11, 2014
Founder and CEO of Vet-Stem, Inc., a leading Regenerative Veterinary Medicine company, Robert J. Harman, DVM presented at The Orthobiologic Institute (TOBI) PRP (Platelet Rich Plasma) and Regenerative Medicine Symposium June 6-7 in Las Vegas. The Symposium with Cadaver Lab boasts over 20 lectures from world-renowned experts in biologics.
Dr. Harman will be presenting on The Future of Biologics: Signposts from Equine Therapies, drawing on a decade of experience developing new products in the Regenerative Veterinary Medicine industry with Vet-Stem, and overseeing the completion of more than 1,000 contract research projects for the development of veterinary and human biotechnology products over his entire career. More recently Dr. Harman brought to the veterinary market Vet-Stems GenesisCS-2 PRP Kit. The kit is optimized for equine use, to provide a rich source of autologous growth factors and bio-scaffolding for use in an area of acute injury, mainly in tendons and ligaments.
Many human medicine practices of the future are first proven in veterinary medicine, with typical use of products and validation from animal data being the flagship for human approvals and protocols. Dr. Harmans company is leading its industry in science-based literature including peer-reviewed studies to prove efficacy and to identify best practices in Regenerative Veterinary Medicine.
TOBI was established to share best practices in cutting-edge PRP and regenerative medicine therapies, drawing global opportunities for physicians to connect within the rapidly growing field. It strives to raise the standards of education and training with intensive hands-on programs and world-class informational curriculums. Courses are intended for Physiatrists, Sports Medicine Physicians, Orthopedists, Rheumatologists and more; addressing areas of the body including shoulder, elbow, wrist/hand, hip, knee, ankle/foot.
About Vet-Stem, Inc. Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. The privately held company is working to develop therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in all animals. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem, Inc. pioneered the use of regenerative stem cells in veterinary medicine. The company holds exclusive licenses to over 50 patents including world-wide veterinary rights for use of adipose derived stem cells. In the last decade over 10,000 animals have been treated using Vet-Stem, Inc.s services, and Vet-Stem is actively investigating stem cell therapy for immune-mediated and inflammatory disease, as well as organ disease and failure. For more on Vet-Stem, Inc. and Veterinary Regenerative Medicine visit http://www.vet-stem.com or call 858-748-2004.
Read this article:
Robert J. Harman, DVM, CEO and Founder of Vet-Stem, Inc. Presents at PRP and Regenerative Medicine Symposium of The ...
Posted: June 14, 2014 at 11:51 am
June 11, 2014 Sophie Langley
Stem cells could be future source for 'eco-friendly' meat, a study has found
The scientific progress that has made it possible to dream of a future in which faulty organs could be regrown from stem cells also holds potential as an ethical and greener source for meat, according to researchers from Wageningen University in The Netherlands.
The researchers suggested in an article published in the Cell Press journal Trends in Biotechnology that every town or village could one day have its very own small-scale, cultured meat factory.
We believe that cultured meat is part of the future, said Cor van der Weele of Wageningen University in The Netherlands.
It is already possible to make meat from stem cells. To prove it, Mark Post, a professor of tissue engineering at Maastricht University, The Netherlands, presented the first lab-grown hamburger in 2013.
However, in their new research paper, Professor van der Weele and Professor Tramper outlined a potential meat manufacturing process, starting with a vial of cells taken from a cell bank and ending with a pressed cake of minced meat. But they said there would be challenges when it came to maintaining a continuous stem cell line and producing cultured meat that was cheaper than meat obtained in the usual way. Most likely, the researchers said, the price of normal meat would first have to rise considerably.
Cultured meat has great moral promise, the researchers wrote. Worries about its unnaturalness might be met through small-scale production methods that allow close contact with cell-donor animals, thereby reversing feelings of alienation. From a technological perspective, village-scale production is also a promising option, they wrote.
Other parts of the future are partly substituting meat with vegetarian products, keeping fewer animals in better circumstances, perhaps eating insects, etc, Professor van der Weele said. This discussion is certainly part of the future in that it is part of the search for a protein transition. It is highly effective in stimulating a growing awareness and discussion of the problems of meat production and consumption, Professor van der Weele said.
Professor van der Weele and coauthor Johannes Tramper said that the rising demand for meat around the world was unsustainable in terms of environmental pollution and energy consumption.
Go here to see the original:
Stem cells could be future source for eco-friendly meat, study
Posted: June 14, 2014 at 11:48 am
TIME Health Heart Disease
Doctors, and especially doctors who do research, dont like to use the words cure or eradicate. They know how dangerous that can be, since the human body is so unpredictable. But Dr. Kiran Musunuru is showing some uncharacteristic swagger about his latest success in lowering heart attack risk among some lucky mice.
Taking advantage of advances in genetic engineering, a team lead by Musunuru, who holds positions at Harvard Universitys Department of Stem Cell and Regenerative Biology and Brigham and Womens Hospital, have edited the genomes of mice and successfully protected them from heart disease. The results, published in the journal Circulation Research, hint at an entirely new way of avoiding the leading killer of Americans by possibly cutting heart attack risk by up to 90%. What has me excited as a cardiologist is that my goal is eradicating disease, says Musunuru. There is no bolder way I can put it. I want to eradicate the disease and this offers one potential way to do it.
MORE: Experimental Cholesterol-Lowering Drug Shows Promise
He admits that it may be 10 years or more before the technique is ready for testing in people, but these first results are enough to justify the research that could make that happen. This approach in general will be a game changer, says Dr. Deepak Srivastava, director of cardiovascular disease and stem cell biology and regenerative medicine at the Gladstone Institutes, who was not affiliated with the study.
Heres how they did it. In 2003, genetic information was gleaned from a French family that carried a genetic mutation giving them low LDL cholesterol, the kind that, when its high, can lead to heart disease. Using a new genetic engineering technique that allows scientists to splice more efficiently into specific locations on a genome, Musunuru was able to essentially bestow the genetic advantage from the French family onto his mice, slowing down production of a protein that normally keeps LDL circulating in the blood. With less of the protein around, less LDL remains in the blood; those with the PCSK9 mutation showed as much as an 88% lower risk of heart disease compared to people without the genetic change.
The genetic monkeying was accomplished with the help of a virus, which has a remarkable ability to get into cells. The virus was injected, along with the DNA-disrupting machinery, into the liver of the mice. Within days, more than half of the liver cells had been genetically edited and the mice showed 35% to 40% less cholesterol in the blood.
So far, says Musunuru, there have been no negative effects of the genetic disruption. But he says more research needs to be done to make sure that introducing the changes wont come with unforeseen consequences. When we go in there we want to make sure we are not introducing new spelling errors in the genome, says Srivastava, who is also using the technique for stem-cell based therapies to treat heart disease. Says Musunuru, I think I can confidently say that with this tool, this technology will work on live, breathing human beings, but we need to figure out the safety; thats the barrier to overcome before we can test these therapies.
MORE: Who Really Needs To Take a Statin?
Drug companies are also working on drug-based ways to interfere with PCSK9, and lower LDL levels, but those therapies are antibodies that bind to the protein that the gene makes and need to be injected, at a doctors office, regularly. The genome editing strategy would be a one-stop therapy that could permanently protect against excessively high cholesterol levels.
Read more here:
A Vaccine for Heart Disease Could Mean No Pills, Lettuce or a Gym
Posted: June 14, 2014 at 11:45 am
Contact Information
Available for logged-in reporters only
Newswise San Antonio, June 10, 2014 Texas Biomedical Research Institute has recruited two new research scientists to its Southwest National Primate Research Center (SNPRC) who will focus on regenerative medicine, working with animal models to develop human stem cell therapies for medical conditions such as Parkinsons disease, degenerative diseases of the eye and muscular dystrophy.
Tiziano Barberi, PhD and Marcel M. Daadi, PhD join Texas Biomed as Associate Scientists in the SNPRC. Barberi comes from the Australian Regenerative Medicine Institute at Monash University in Melbourne, Australia and Daadi arrives from Palo Alto, CA where he was part of the Consulting Faculty of Stanford Universitys Department of Neurosurgery. He is also President and Chief Scientific Officer of NeoNeuron LLC.
Dr. Barberi and Dr. Daadi are significant additions to our regenerative medicine research program, Texas Biomed President and CEO Kenneth P. Trevett said. Both have focused on stem cell research, have published significant research results in peer review journals and received recognition for their leading roles within research teams and at institutions. Regenerative medicine is a major focus for Texas Biomed, where we have new facilities and financial resources dedicated for that purpose, he said. We also look to expand our work with other institutions and groups in San Antonio to promote progress in this field. Dr. Barberi and Dr. Daadi both have strong backgrounds in developing collaborative efforts, and we look forward to the contributions they will make in this important research arena.
Barberi, a native of Italy, had been one of 15 Chief Investigators of the Stem Cells Australia Consortium for stem cell research and Group Leader for the Australian Regenerative Medicine Institute. With a laboratory research focus on the directed differentiation of human pluripotent stem cells (hESC and iPSC) into specific developmental fates, his research aims are to provide tools for human development studies, in vitro disease modeling and a cell therapeutics approach to disease. He described in a seminal work a method to obtain all the clinically relevant neuronal subtypes from mESC, and was the first to have directed differentiation of hESC into mesenchymal precursors and into the progenitor cells forming the skeletal muscle system.
Prior to his work in Australia, Barberi was head of the Laboratory of Stem Cells and Development at the Beckman Research Institute of City of Hope in Duarte, CA. During the time spent at City of Hope, Barberi was awarded the prestigious New Faculty Award from the California Institute for Regenerative Medicine (CIRM). He is an invited reviewer for a number of stem cell-related research journals and is a grant reviewer/assessor for research programs in Canada, Australia, New Zealand and the European Union.
Daadi has unique academia and industry experiences bridging basic and translational research. He comes to Texas Biomed from the San Francisco bay area where he founded a biotechnology company, NeoNeuron, focused on developing therapies for treating neurological disorders. He served as Director of Stem Cell Research, CIRM Disease Team Stroke Neural Transplant Program at Stanford University School of Medicine and Director of the Parkinson's Disease Program at the Sanford Burnham Medical Research Institute, Layton Biosciences Inc and NeuroSpheres LLC.
At Stanford University, Daadi developed a novel technology to purify homogenous populations of neural stem cells from human pluripotent stem cells and coax them to specific types of neurons that can be used for brain repair. His research is paving the way for clinical trials to treat patients with devastating neurological disorders, such as Parkinsons disease, stroke and traumatic brain injury. He seeks to expand on the capabilities of the SNPRC and to build new collaborative programs and projects in stem cell research with colleagues at the University of Texas Health Science Center at San Antonio and the University of Texas at San Antonio.
Daadi serves as editor and reviewer for many peer review journals. He is a permanent member on the National Institutes of Health Grant Review Committee, The Maryland Stem Cell Research Fund and serves on many other national and international Grant Review Committees.
See the article here:
Texas Biomed Regenerative Medicine Program Expands With Two New Research Scientists
Posted: June 13, 2014 at 8:44 pm
Biochemistry of Stem Cells
By: Global Medical Training Network [GMTN]
See more here:
Biochemistry of Stem Cells - Video
Posted: June 13, 2014 at 8:44 pm
Dr Nathan Newman Explains LUMINESCE Jeunesse Global
http://renate23.jeunesseglobal.com Dr. Nathan Newman explains how Adult Stem Cells are Revolutionizing medicine and how they #39;re Already being used in treatment of cosmetic and reconstructive...
By: Renate Delaforce
Read more here:
Dr Nathan Newman Explains LUMINESCE Jeunesse Global - Video
Posted: June 13, 2014 at 8:44 pm
Stem Cells, Binmimetic Polymers, and the Promise of Regenerative Medience: Kevin Healy
By: citrisuc
Read more:
Stem Cells, Binmimetic Polymers, and the Promise of Regenerative Medience: Kevin Healy - Video
